Proactive Investors - Run By Investors For Investors

Ventripoint says Johns Hopkins doctor cited VMS+ heart analysis system’s clinical feasibility at Milan conference

Dr Shelby Kutty gave a presentation on a study conducted at the University of Nebraska Medical Center Children's Hospital
An illustration of the cardiovascular system
Ventripoint says its system provides a cost-effective approach to volumetric measurements of all four heart chambers

Ventripoint Diagnostics Ltd (CVE:VPT) (OTCMKTS:VPTDF) said Friday that a Johns Hopkins doctor cited the clinical feasibility of the company’s VMS+ 3.0 heart analysis system at a cardiovascular imaging conference in Milan.

The Toronto-based medical care device company said in a press release that Dr Shelby Kutty recently gave a presentation on a study of the system at EuroEcho 2018. The study was conducted at the University of Nebraska Medical Center Children's Hospital, according to Ventripoint.

READ: VentriPoint Diagnostics reveals that University of Chicago will assess its heart analysis system

"This study presented at EuroEcho 2018 demonstrates the clinical feasibility of quantifying right and left ventricular volumes and function using VMS+ on two- and three-dimensional images acquired from multiple cardiac ultrasound systems,” Shutty said in a statement.

More than 4,200 people attended the conference, according to Ventripoint.

The response to the system at EuroEcho 2018 indicates a significant need for a cost-effective and accurate approach to volumetric measurements of all four chambers of the heart, according to Mehran Mehrtash, vice president for worldwide distributor sales at Ventripoint.

“The VMS+ technology sets us apart and can make a valuable difference in patient outcomes," Mehrtash said.

The system is not yet available for commercial sale and is for investigational use only, according to Ventripoint.

Shares climbed C$0.01 to C$0.17 in Thursday’s Canadian trading.

Last month, the company told investors that the University of Chicago's medical center was preparing to study the VMS+ system.

Contact Dennis Fitzgerald at [email protected]

View full VPT profile View Profile

VentriPoint Diagnostics Ltd. Timeline

Related Articles

April 30 2019
We take a look at a company with a unique approach to drug development that may ultimately help big pharma replenish its pipeline
test tubes
May 07 2019
Here we take a closer look at Arix Biosciences PLC (LON:ARIX), a listed venture capital company that doesn’t appear to be receiving the recognition it deserves
PT exercises
December 19 2018
The Californian company is a bet on an industry that is in need of transformation
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use